A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).

Authors: Yohann Loriot, Arlene O. Siefker-Radtke, Terence W. Friedlander, Andrea Necchi, Alexander Z Wei, Srikala S. Sridhar, Benjamin Garmezy, Santiago Arroyo, Emma Gartside, Jie Liu, Carly Campbell, Justin Bader, Daniel P. Petrylak

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.tps898

Source: Full article

---

Abstract

TPS898